DSIP

Melatonin mainly signals darkness and regulates the timing of sleep. DSIP was named for raising delta (slow-wave) EEG activity in rabbits, and proponents say it changes the *quality* of sleep, not just the timing. In people the evidence is thin: a 1992 double-blind trial in 16 adults with chronic insomnia found weak effects and concluded DSIP was "not likely to be of major therapeutic benefit." No trial has compared it with melatonin or prescription hypnotics, so the claim that it lacks their 'hangover' effect is untested.

Users commonly report morning grogginess mainly at higher doses, and many describe lowering the dose when it happens. Lab studies found DSIP breaks down quickly in blood, which fits with short-lived effects, but no trial has measured next-day drowsiness after subcutaneous use.

Vendor and forum protocols describe nightly use for 4-8 weeks, or as-needed use after travel or during periods of high stress. No study has tested either schedule or looked at tolerance or dependence; that is a gap, not evidence of safety. At the July 2026 FDA advisory meeting, Public Citizen cited lab and rat data suggesting DSIP may act on the opioid system. Cycling is a common community practice.

Users commonly describe a gradual sense of relaxation within 30-60 minutes rather than a sudden 'knock-out' effect like a sleeping pill. These are self-reports; the human trials gave DSIP intravenously and didn't track this.